We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Access expired on Wednesday, July 17, 2019

This content was originally shared by a registered user, but access has expired. Create a free account to gain permanent access to all PracticeUpdate content.

Already Have An Account? Log in Now

story of the week
Published in Oncology

Journal Scan / Research · June 12, 2019

Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer

The New England Journal of Medicine

 

Additional Info

Disclosure statements are available on the authors' profiles:

The New England Journal of Medicine
Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer
N. Engl. J. Med 2019 Jun 02;[EPub Ahead of Print], T Golan, P Hammel, M Reni, E Van Cutsem, T Macarulla, MJ Hall, JO Park, D Hochhauser, D Arnold, DY Oh, A Reinacher-Schick, G Tortora, H Algül, EM O'Reilly, D McGuinness, KY Cui, K Schlienger, GY Locker, HL Kindler

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading